C7287

Canrenoic acid potassium salt

powder

• Synonim(y): 17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid, Potassium canrenoate
• Wzór liniowy: C₂₂H₃₀O₄K
• Numer CAS: 2181-04-6
• Masa cząsteczkowa: 397.57
• NACRES: NA.77
• PubChem Substance ID: 24892953
• UNSPSC Code: 12352106
• EC Number: 218-554-9
• MDL number: MFCD05662375
• Form: powder

Właściwości

• form: powder
• Quality Segment: 100
• color: light yellow to tan
• SMILES string: [K].[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)CCC(O)=O)[C@]1([H])C=CC4=CC(=O)CC[C@]24C
• InChI: 1S/C22H30O4.K.H/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);;/t16-,17+,18+,20+,21+,22-;;/m1../s1
• InChI key: YLXFIHIYNGPPSF-HUHWECDNSA-N

Opis

Application

Canrenoic acid potassium salt has been used as a human uridine 5′-diphospho (UDP)-glucuronosyltransferase inhibitor to study its effects on trifluoperazine (TFP) substrate selectivity. It has also been used to study its effects on the formation of aldosterone 18-glucuronide (ALDO 18β-G) in recombinant UDP-Glucuronosyltransferase-2B7 (UGT2B7), human liver (HLM) and human kidney cortical (HKCM) microsomes.

Biochem/physiol Actions

Competitive aldosterone receptor antagonist.

Competitive aldosterone receptor antagonist. Potassium canrenoate reduces the effects of aldosterone-induced increases in blood pressure and in cardiovascular fibrosis in animals with high sodium intake. It is used clinically for its anti-fibrotic effects. At higher doses it is genotoxic to liver and increases tumor incidence in rodent models.

Analysis Note

Aqueous solutions may contain some insoluble material.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS07
• Słowo ostrzegawcze: Warning
• Kody zagrożeń: H302
• Hazard Classifications: Acute Tox. 4 Oral
• Klasa składowania: 11 - Combustible Solids
• Co się dzieje?: WGK 3
• PPE (środki ochrony indywidualnej): dust mask type N95 (US), Eyeshields, Gloves